Terekeci, Murat HakanNalbant, SelimÖzgürtaş, TanerÇelik, SerkanTapan, SerkanSanisoğlu, Yavuz S.Şahan, BurakSayan, ÖzkanKüçükardalı, YaşarTop, CihanÖktenli, Çağatay2024-07-122024-07-122009Terekeci, M. H., Nalbant, S., Özgürtaş, T., Çelik, S., Tapan, S., Sanisoğlu, Y. S., Şahan, B., Sayan, Ö., Küçükardalı, Y., Top, C. ve Öktenli, Ç. (2009). Increased circulating asymmetric dimethylarginine (ADMA) levels in active stage of Behçet’s Syndrome. Aktuelle Rheumatologie, Thieme Publishing Group. 34(2), s. 121-125.0341-051Xhttps://www.thieme-connect.com/products/ejournals/abstract/10.1055/s-2008-1027716https://hdl.handle.net/20.500.12415/3499There is little evidence in the literature about circulating asymmetric dimethylarginine (ADMA) levels in Behçet's syndrome (BS). The aim of the present study was 1. to measure the levels of ADMA in male patients with BS, 2. to compare ADMA levels with healthy volunteers, and 3. to evaluate whether there is any difference between patients both with / without thrombosis and in active / inactive stage. In patients with BS, CRP levels were higher than controls. The mean ADMA and C-reactive protein (CRP) levels were significantly higher in active stage patients and patients with thrombosis than in patients during the inactive stage and without thrombosis. In conclusion, we did not find any significant difference in ADMA levels between patients with BS and healthy controls. Serum ADMA concentrations, however,eninfo:eu-repo/semantics/openAccessBehçet's diseaseasymmetric dimethylarginineendothelial dysfunctionthrombosisactive stageArticle1252Q412134